1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Drugs In Development, 2022, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Pemphigus Vulgaris - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology).
- The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Pemphigus Vulgaris - Overview
- Pemphigus Vulgaris - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Pemphigus Vulgaris - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Pemphigus Vulgaris - Companies Involved in Therapeutics Development
- Argenx SE
- BioXpress Therapeutics SA
- Cabaletta Bio Inc
- Daewoong Pharmaceutical Co Ltd
- Evopoint Bioscience Co Ltd
- HanAll Biopharma Co Ltd
- iBio Inc
- ImmunoWork LLC
- Octagon Therapeutics Inc
- Pharmapraxis
- Serpin Pharma LLC
- Topas Therapeutics GmbH
- Pemphigus Vulgaris - Drug Profiles
- batoclimab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile
- Product Description
- Mechanism Of Action
- DSG3-CAART - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DSG3/1-CAART - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DWP-212525 - Drug Profile
- Product Description
- Mechanism Of Action
- efgartigimod alfa - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OW-177 - Drug Profile
- Product Description
- Mechanism Of Action
- Pemphigus Vulgaris - Drug Profile
- Product Description
- Mechanism Of Action
- rituximab biobetter - Drug Profile
- Product Description
- Mechanism Of Action
- rituximab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- rituximab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- SP-16 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TPM-203 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- XNW-1011 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Pemphigus Vulgaris - Dormant Projects
- Pemphigus Vulgaris - Discontinued Products
- Pemphigus Vulgaris - Product Development Milestones
- Featured News & Press Releases
- Sep 10, 2022: Cabaletta Bio presents new interim data from the DesCAARTes Phase 1 Trial at the 31st EADV Congress
- Sep 10, 2022: Cabaletta Bio to present data at the 31st EADV Congress and provides update on DesCAARTes trial
- May 18, 2022: Cabaletta Bio presents updated interim DesCAARTes trial phase 1 data at the ASGCT 25th Annual Meeting
- May 02, 2022: Cabaletta Bio to present DSG3-CAART clinical data at Upcoming Scientific Meetings in May
- Dec 14, 2021: Cabaletta Bio reports top-line biologic activity data from two lowest dose cohorts in DesCAARTes trial in patients with mucosal pemphigus vulgaris
- Nov 15, 2021: Zai Lab announces first patient dosed in Greater China in global registrational clinical trial of efgartigimod in pemphigus
- Nov 01, 2021: Cabaletta Bio reports clinical data from the third dose cohort in DesCAARTes trial in patients with mPV
- Aug 18, 2021: Cabaletta Bio reports clinical data from the second dose cohort in DesCAARTes trial in patients with mPV
- May 03, 2021: Cabaletta Bio reports acute safety data from the first dose cohort in DesCAARTes trial
- Dec 08, 2020: Cabaletta Bio announces first patient dosed in Landmark DesCAARTes trial of DSG3-CAART for treatment of mucosal-dominant pemphigus vulgaris
- Aug 25, 2020: Cabaletta Bio announces publication of comprehensive preclinical study results for DSG3-CAART in pemphigus vulgaris
- May 06, 2020: Cabaletta Bio receives FDA Fast Track Designation for DSG3-CAART for the treatment of Mucosal Pemphigus Vulgaris
- Jan 29, 2020: FDA grants DSG3-CAART orphan drug designation for the treatment of pemphigus vulgaris
- Dec 18, 2019: Topas Therapeutics announces first patient enrolled in phase 1 trial with TPM203 in pemphigus vulgaris
- Oct 01, 2019: Cabaletta Bio receives IND clearance from FDA to initiate first clinical trial of DSG3-CAART in patients with Mucosal Pemphigus Vulgaris
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Pemphigus Vulgaris, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pemphigus Vulgaris - Pipeline by Argenx SE, 2022
- Pemphigus Vulgaris - Pipeline by BioXpress Therapeutics SA, 2022
- Pemphigus Vulgaris - Pipeline by Cabaletta Bio Inc, 2022
- Pemphigus Vulgaris - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Pemphigus Vulgaris - Pipeline by Evopoint Bioscience Co Ltd, 2022
- Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, 2022
- Pemphigus Vulgaris - Pipeline by iBio Inc, 2022
- Pemphigus Vulgaris - Pipeline by ImmunoWork LLC, 2022
- Pemphigus Vulgaris - Pipeline by Octagon Therapeutics Inc, 2022
- Pemphigus Vulgaris - Pipeline by Pharmapraxis, 2022
- Pemphigus Vulgaris - Pipeline by Serpin Pharma LLC, 2022
- Pemphigus Vulgaris - Pipeline by Topas Therapeutics GmbH, 2022
- Pemphigus Vulgaris - Dormant Projects, 2022
- Pemphigus Vulgaris - Discontinued Products, 2022
- Number of Products under Development for Pemphigus Vulgaris, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Argenx SE
- BioXpress Therapeutics SA
- Cabaletta Bio Inc
- Daewoong Pharmaceutical Co Ltd
- Evopoint Bioscience Co Ltd
- HanAll Biopharma Co Ltd
- iBio Inc
- ImmunoWork LLC
- Octagon Therapeutics Inc
- Pharmapraxis
- Serpin Pharma LLC
- Topas Therapeutics GmbH
